# Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

> **NCT04921904** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor Research Institute** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Esophageal Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT04921904
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-11
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921904, "Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04921904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*